Table 2.
Risk of predialysis sK+ concentration >5.5 or >6.0 mmol/L at LIDI visits during the 4-week evaluation period following the initial hyperkalemic event.
| LIDI visit | Predialysis sK+ at randomization (visit 4, day 1) (mmol/L) | |||
|---|---|---|---|---|
| <5.5, n = 14 | 5.5 to <6.0, n = 37 | 6.0 to <6.5, n = 21 | ≥6.5, n = 14 | |
| Incidence of predialysis sK + >5.5 mmol/L | ||||
| Visit 12 (day 36) | 8/13 (61.5) | 19/33 (57.6) | 10/18 (55.6) | 11/13 (84.6) |
| Visit 13 (day 43) | 4/12 (33.3) | 18/33 (54.5) | 15/20 (75.0) | 10/13 (76.9) |
| Visit 14 (day 50) | 5/12 (41.7) | 23/33 (69.7) | 17/21 (81.0) | 12/13 (92.3) |
| Visit 15 (day 57) | 5/14 (35.7) | 24/33 (72.7) | 13/21 (61.9) | 8/12 (66.7) |
| Overall | 22/51 (43.1) | 84/132 (63.6) | 55/80 (68.8) | 41/51 (80.4) |
|
| ||||
| Incidence of predialysis sK + >6.0 mmol/L | ||||
| Visit 12 (day 36) | 2/13 (15.4) | 3/33 (9.1) | 4/18 (22.2) | 8/13 (61.5) |
| Visit 13 (day 43) | 1/12 (8.3) | 4/33 (12.1) | 6/20 (30.0) | 6/13 (46.2) |
| Visit 14 (day 50) | 3/12 (25.0) | 10/33 (30.3) | 9/21 (42.9) | 10/13 (76.9) |
| Visit 15 (day 57) | 2/14 (14.3) | 10/33 (30.3) | 2/21 (9.5) | 7/12 (58.3) |
| Overall | 8/51 (15.7) | 27/132 (20.5) | 21/80 (26.3) | 31/51 (60.8) |
Data are shown as the number (%) of hyperkalemic events. Hyperkalemia was defined as sK+ >5.5 or >6.0 mmol/L after the LIDI. No imputation of missing data was conducted. For each randomization predialysis sK+ subgroup, the probability of whether patients with hyperkalemia will be hyperkalemic (sK+ >5.5 or >6.0 mmol/L) at subsequent visits was calculated as follows: [Number of hyperkalemic events/total number of possible hyperkalemic events based on patients with evaluable data] × 100. LIDI, long interdialytic interval; sK+, serum potassium.